Literature DB >> 6147221

Triazolam protein binding and correlation with alpha-1 acid glycoprotein concentration.

P D Kroboth, R B Smith, M I Sorkin, M R Silver, R Rault, M Garry, R P Juhl.   

Abstract

On two occasions separated by a minimum of 1 wk, plasma was obtained from 12 patients (aged 18 to 73 yr) on dialysis after an overnight fast. Samples were assayed for albumin and alpha 1-acid glycoprotein (AGP) concentrations. 14C-Triazolam was added to each sample to a final concentration of 5 ng/ml. Protein binding was determined by equilibrium dialysis. Unbound triazolam ranged from 6.4% to 15.4% (mean = 10.0%). AGP concentrations ranged from 71.8 to 205.1 mg% (mean = 123.4 mg%). Triazolam binding ratio (bound/unbound concentration) correlated with AGP concentration (r2 = 0.69) but not with albumin concentration, age, or sex. This correlation was verified by adding AGP in varying amounts to control plasma.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6147221     DOI: 10.1038/clpt.1984.191

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

1.  Influence of menstrual cycle phase on serum concentrations of alpha 1-acid glycoprotein.

Authors:  R C Parish; C Spivey
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of non-opiate abused drugs.

Authors:  U Busto; R Bendayan; E M Sellers
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

3.  The plasma protein binding of basic drugs.

Authors:  P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

Review 4.  Plasma protein binding of drugs in the elderly.

Authors:  S M Wallace; R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

Review 5.  Pharmacokinetics of the newer benzodiazepines.

Authors:  P D Garzone; P D Kroboth
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

6.  Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.

Authors:  P D Kroboth; R B Smith; M R Silver; R Rault; M I Sorkin; J B Puschett; R P Juhl
Journal:  Br J Clin Pharmacol       Date:  1985-06       Impact factor: 4.335

Review 7.  Clinical pharmacokinetics of alprazolam. Therapeutic implications.

Authors:  D J Greenblatt; C E Wright
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.